Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 4/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | CDC25B | P30305 | 1/20 | 0.39 |
| ▸ | ELANE | P08246 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | ADRB2 | P07550 | 2/20 | 0.37 |
| ▸ | ADRB1 | P08588 | 2/20 | 0.37 |
| ▸ | ADRB3 | P13945 | 2/20 | 0.37 |
| ▸ | ABCB1 | P08183 | 3/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.35 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1979973 | 0.91 | ALDH1A1 (0.44) | TSHRALDH1A1HTTKDM4ELMNA | |
| SCHEMBL15092822 | 0.86 | ALDH1A1 (0.42) | TSHRALDH1A1CDC25BELANEKDM4E | |
| SCHEMBL15093081 | 0.85 | ALDH1A1 (0.40) | TSHRALDH1A1HTTCDC25BELANE | |
| SCHEMBL1980987 | 0.85 | LMNA (0.46) | TSHRALDH1A1HTTELANELMNA | |
| SCHEMBL15092737 | 0.84 | TSHR (0.44) | TSHRALDH1A1CDC25BELANEKDM4E | |
| SCHEMBL1913998 | 0.82 | ELANE (0.49) | TSHRALDH1A1CDC25BELANEKDM4E | |
| SCHEMBL15093123 | 0.82 | CDC25B (0.44) | TSHRALDH1A1CDC25BELANEKDM4E | |
| SCHEMBL15092965 | 0.82 | ELANE (0.54) | TSHRALDH1A1CDC25BELANEKDM4E | |
| SCHEMBL15093047 | 0.82 | TSHR (0.49) | TSHRALDH1A1HTTCDC25BELANE | |
| SCHEMBL15093223 | 0.82 | TSHR (0.37) | TSHRALDH1A1HTTKDM4ELMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8729312-B2 | Derivatives of novel peroxides, method of preparation thereof and use thereof in human medicine as well as in cosmetics for the treatment or prevention of acne | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2014-05-20 | — | — | US | claimed |
| US-20130178648-A1 | DERIVATIVES OF NOVEL PEROXIDES, METHOD OF PREPARATION THEREOF AND USE THEREOF IN HUMAN MEDICINE AS WELL AS IN COSMETICS FOR THE TREATMENT OR PREVENTION OF ACNE | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2013-07-11 | — | — | US | claimed |
| US-8729312-B2 | Derivatives of novel peroxides, method of preparation thereof and use thereof in human medicine as well as in cosmetics for the treatment or prevention of acne | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2014-05-20 | — | — | US | disclosed |
| US-20130178648-A1 | DERIVATIVES OF NOVEL PEROXIDES, METHOD OF PREPARATION THEREOF AND USE THEREOF IN HUMAN MEDICINE AS WELL AS IN COSMETICS FOR THE TREATMENT OR PREVENTION OF ACNE | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2013-07-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130178648-A1 | DERIVATIVES OF NOVEL PEROXIDES, METHOD OF PREPARATION THEREOF AND USE THEREOF IN HUMAN MEDICINE AS WELL AS IN COSMETICS FOR THE TREATMENT OR PREVENTION OF ACNE | GPX4, LPO, GPX1 | TSHR 2165/4885ALDH1A1 163/4885HTT 3107/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.